Life Technologies to support SMS-IC
The Ion Proton sequencing platform, which is the primary tool to drive discovery and genetic analysis, will translate chemical information into digital data through a semiconductor chip. Life
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.
The assays are used to determine hemoglobin variants and diabetes risk, using Bruker´s Matrix-Assisted Laser Desorption Ionization (MALDI) Biotyper platform for clinical mass spectrometry and based on intellectual